Related Experiment Video
Updated: Aug 6, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Determinants of Glycemic Control with Automated Insulin Delivery in adults living with type 1 diabetes: A 12-Month
Michael Joubert1, Jean-Baptiste Julla2, Eric Renard3
1Department of Endocrinology, University Hospital of Caen, UNICAEN, France.
Objective:
To identify baseline determinants of achieving international continuous glucose monitoring (CGM) targets after 12 months of automated insulin delivery (AID) in adults with type 1 diabetes.
Research Design And Methods:
This predefined sub-analysis of the nationwide French OB2F registry included adults with type 1 diabetes initiating MiniMed 780G or Tandem Control-IQ in 2022. Participants required ≥14 consecutive days of CGM data at baseline and 12 months. The primary outcome was achievement of combined CGM targets at 12 months, defined as TIR >70% and TBR <4%. Baseline predictors were assessed using multivariable logistic regression.
Results:
Among 1,058 adults, 43% achieved combined CGM targets at 12 months (52% of MiniMed 780G users and 36% of Tandem Control-IQ users). Better baseline metabolic control, including higher TIR and lower HbA1c, TAR, GMI, and glucose variability, was independently associated with target achievement across both systems. Lower baseline TBR predicted target achievement only in MiniMed 780G users. GRI improved in both systems, from 44.1±19.4 to 30.2±13.6 with MiniMed 780G and from 49.4±20.0 to 36.7±14.9 with Tandem Control-IQ.
Conclusions:
Baseline glycaemic profile is the main determinant of achieving international CGM targets after AID initiation in adults with type 1 diabetes, despite substantial improvement in those with poorer baseline control.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Type I Diabetes I: Introduction
Type I Diabetes III: Clinical Manifestations